No Data
No Data
Express News | Microchip Biotech: Sidabendamide combined with R-CHOP for the treatment of diffuse large B-cell lymphoma approved for marketing
Microchip Biotech (688321.SH): Net loss of 18.30.46 million yuan in the first quarter
Gelonghui, April 28, 丨 Microchip Biotech (688321.SH) released its report for the first quarter of 2024. During the reporting period, it achieved operating income of 131 million yuan, an increase of 22.60% over the previous year; net profit attributable to shareholders of listed companies - 183,046 million yuan; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss of 219.761 million yuan; and basic earnings per share - 0.0448 yuan.
Revenues Tell The Story For Shenzhen Chipscreen Biosciences Co., Ltd. (SHSE:688321) As Its Stock Soars 26%
Shenzhen Chipscreen Biosciences Co., Ltd. (SHSE:688321) shareholders would be excited to see that the share price has had a great month, posting a 26% gain and recovering from prior weakness. Unfor
Chipscreen Biosciences Offers Sell-Back Option for Microchip Convertible Bond Holders
Shenzhen Chipscreen Biosciences (SHA:688321) said holders of its microchip convertible bonds will have the option to sell back their bonds to the company at 100.49 yuan per unit, according to a filing
Microchip Biotech: “Microchip Bonds Transfer” can be resold
Shenzhen Microchip Biotechnology Co., Ltd. announced that the additional resale clause for “Microchip Bonds Transfer” is in effect. The resale application period is from April 29, 2024 to May 8, 2024. The resale price is RMB 100.49 per sheet (including current interest). The transaction will continue during the resale period, but the share conversion will stop.
Microchip Biotech (688321): 2024 enters the harvest year of Microchip's innovative drugs
The company's performance in 2023 was mediocre. In 2023, the company's revenue was 520 million yuan, down 1.2% year on year. Net profit to mother was 88.84 million yuan, up 408.1% year on year, after deducting loss of 220 million yuan in non-net profit.
No Data